Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
Balanced anticoagulation is essential in patients requiring both preventive and therapeutic management of thromboembolic conditions. Low molecular weight heparins (LMWH) offer reliable anticoagulant activity with consistent clinical outcomes in a wide range of medical settings.
ENOXABARA® 60 mg is developed by RIHCA and marketed through RAWIACARE, providing a flexible anticoagulation solution suitable for moderate-risk patients and controlled treatment protocols across global healthcare environments — To Share • To Care • To Inspire.
ENOXABARA® 60 mg is designed for both prevention and treatment of thromboembolic disorders. It provides effective inhibition of factor Xa activity, supporting controlled anticoagulation.
| Specifications Table | |
| Parameter | Details |
| Brand Name | ENOXABARA® |
| Generic Name | Enoxaparin Sodium |
| Arabic Name | إينوكسابارا إينوكسابارين |
| Category | Anticoagulants |
| Therapeutic Area | Low Molecular Weight Heparin (LMWH) |
| Dosage Form | Injection |
| Strength | 60 mg |
| Volume | 0.6 ml |
| Route / Type | Subcutaneous (Anti-Xa) |
| Developed By | RIHCA |
| Marketed By | RAWIACARE |
| Prevention and treatment of Deep Vein Thrombosis (DVT) |
| Management of Venous Thromboembolism (VTE) |
| Post-surgical anticoagulant support |
| Anticoagulant therapy in moderate-risk patients |
| Hospital and clinical treatment protocols |
| It is used for both prevention and treatment of thromboembolic conditions such as Deep Vein Thrombosis (DVT) and Venous Thromboembolism (VTE). |
| It inhibits factor Xa activity, reducing clot formation and supporting stable blood circulation. |
| Patients requiring balanced anticoagulation for both preventive and therapeutic purposes under medical supervision. |
| Hospitals, clinics, surgical units, and internal medicine departments. |
Subcutaneous injection.
| 40 mg, 60 mg, 80 mg |
